Recently, diverse computational approaches explored for screening the drug molecules for COVID19 treatment. Molecular docking of Lopinavir, Darunavir and Ritonavir reported against the modelled structure of COVID19 proteases, coronavirus endopeptidase C30 (CEP_C30) and papain-like viral protease (PLVP) . MM-PBSA-WSAS (Molecular dynamics simulations followed by binding free energy calculations using an endpoint method) employed for Fast Identification of Possible Drug against COVID-19 protease . Anti-HCV drugs, Sofosbuvir, IDX-184, Ribavirin, and Remidisvir reported promising drug candidates with a docking approach against modelled COVID-19 RNA dependent RNA polymerase (RdRp) . Hirokawa et al., (2020) identified one hundred and several dozen potentially candidate drugs for 3CL protease inhibitors, which are already approved as antiviral, HIV protease inhibitors, antibacterial or antineoplastic agents with in silico docking-based screening approach, which combines molecular docking with a protein-ligand interaction fingerprint (PLIF) scoring method.